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Abstract Purpose To describe a case of HSV2
acute retinal necrosis (ARN) diagnosed and moni-
tored with quantitative polymerase chain reaction
(PCR) in ocular fluids. Design Case report. Methods
Quantitative PCR was performed in the aqueous
humor (AH) and vitreous using primers specific for
herpes virus. Results A positive PCR was found for
HSV2 in the AH ([100,000,000 viral copies -
8.00 log/ml). After therapy, another anterior chamber
tap showed a reduction of the viral load at 4.28 log/ml
(19205 copies), confirming the efficacy of the treat-
ment. After six months, PCR on the vitreous still
showed the presence of HSV2 viral particles in the
eye (3.14 log DNA copies/ml, 1379 copies) although
the lesion was healed. Conclusions This case dem-
onstrates that PCR is useful to detect viral DNA in
AH and vitreous and to monitor viral activity and
therapeutic response. Viral DNA persists in ocular
fluids for months in the presence of a healed
infection.
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Introduction
A 31-year-old South-American woman was referred
for acute and progressive visual loss affecting her left
eye (LE), with diffuse ocular pain, photophobia, and
redness.
Examination revealed a visual acuity of 20/100 in
LE and 20/20 in right eye (RE) without correction.
Anterior segment disclosed a mild nongranulomatous
inflammation in the LE. Intra-ocular pressure was
10 mmHg in both eyes. Fundus examination of the
LE revealed a vitritis (3 + cells), a disc edema,
occlusive vasculitis, and areas of inferior retinal
necrosis (Fig. 1). An acute retinal necrosis (ARN)
was suspected and the patient was hospitalized.
An anterior chamber tap was then performed
for Herpexvirus1 (HSV1), Herpesvirus2 (HSV2),
Varicella-Zoster virus (VZV), Cytomegalovirus
(CMV), Epstein-Barr virus (EBV), and Toxoplasmo-
sis PCR. The patient was immediately treated with a
combination of iv aciclovir (3 9 10 mg/kg/8 h) and
oral valganciclovir (2 9 450 mg/d) as well as one
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intravitreous injection of ganciclovir (2000 lg).
Topical steroids and mydriatics were also prescribed.
Blood tests revealed a sedimentation rate of 8 mm/h
(N = 1–12), and a normal white blood count. An
extensive uveitis work-up looking for infectious and
noninfectious causes was negative, in particular
serologies for borrelia burgdorferi, treponema palli-
dum, leptospirosis, rickettsiosis, brucellosis, and
toxoplasmosis. Serologies for herpes virus revealed
past exposure (HSV IgG 1.19, N \ 0.2 and IgM 0.12,
N \ 0.2).
Quantitative PCR analysis of the AH was positive
for HSV 2 [ 100,000,000 viral copies (8.00 log/ml)
and all other PCR tests were negative. After 2 weeks
of therapy, we performed another anterior chamber
tap and results showed a reduction of the viral load at
4.28 log/ml (19205 copies), confirming the efficacy
of the antiviral treatment (Fig. 2).
Aciclovir treatment was continued for two additional
weeks iv, then orally for 3 months. Valganciclovir
(2 9 450 mg/day) was prescribed during the first
2 weeks. No systemic (blood count, renal function) or
local adverse effects were observed. Complete cicatri-
zation of the main necrotic lesion was noted. After
7 months, a vitrectomy was performed to clear the
vitreous inflammatory opacification. PCR on the vitre-
ous sample still showed the presence of HSV2 viral
particles in the eye (3.14 log DNA copies/ml, 1379
copies).
We followed the patient during 24 months. No
ocular complications were recorded and no reactiva-
tion/bilateralization of the infection was observed.
Final visual acuity was 1.0 in both eyes. Another
anterior chamber tap, performed at 10 months,
revealed negative herpes virus PCR.
Comment
ARN was first described by Urayama and associates in
1971 [1] and subsequently was shown to be most
frequently caused by herpes simplex virus type 1 or 2
and less frequently by the varicella zoster virus. This
infection has potentially devastating consequences on
ocular function and is frequently complicated by
secondary retinal detachment and bilateral involve-
ment. The diagnosis is initially based on clinical
features (areas of retinal necrosis, occlusive vasculitis,
vitritis) [2]. ARN occurs both in immunosuppressed
and apparently immunocompetent patients. A study
has however shown that, even in patients thought to be
immunocompetent, there is a degree of immune
dysfunction [3]. The recommended treatment of
ARN includes initial high dose of intravenous aciclovir
Fig. 1 Color picture of the left eye: optic nerve head edema,
occlusive vasculitis, and area of retinal necrosis inferiorly
(arrow)
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Fig. 2 Viral load kinetic over disease course. Abbreviations:
AZ: aciclovir, VG: valganciclovir, GCV ivt: intravitreous
ganciclovir, AH: aqueous humor, V: vitreous
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(3 9 10 mg/kg/8 h) for 10 days followed by 3 months
of oral suppressive treatment with aciclovir. Intravi-
treal therapy (ganciclovir, foscarnet), topical steroids,
and mydriatics are considered useful as adjuvant
therapy to control infection and inflammation.
Although diagnosis is initially clinical, formally
microbiological and particularly virological analysis
of ocular fluids (AC and/or vitreous) is needed to
identify the causative agent and guide therapy [4].
The possible involvement of a herpes-group virus
as the causative agent of ARN was first suggested by
Culbertson in 1982, after histopathological and
electron microscopy evaluation of an enuclated eye
[5]. In 2000, Ganatra et al. found in a group of 28
patients with ARN, HSV1 in 7 patients, HSV2 in 6
patients and CMV in one patient [6]. The association
of ARN with herpetic encephalitis or disseminated
herpes in the neonate has also been reported [7]. It
has been suggested that, in patients under 25 years
old, ARN is more likely to be caused by HSV2. Tran
et al. [8] described 11 cases of HSV2-related ARN
syndrome in patients aged from 10 to 57 years. At the
end of the follow-up period, five eyes (41.7%)
showed improvement of visual acuity of two or more
lines. Final visual acuity was 20/60 or better in four
eyes (33.3%), 20/400 or better in four eyes (33.3%),
and less than 20/400 in four eyes. In our patient, after
a follow-up of 24 months, vision returned to 20/20
with no bilateralization and/or reactivation of the
infection.
PCR is a sensitive and specific method performed
for detection of viral DNA in ocular samples from
immunocompetent and immunocompromised patients
presenting with viral retinitis. It has been used as a tool
for the determination of causal agents in ARN
syndrome. In our case, results of the AH examination
were positive for HSV2 with initially a very high viral
load confirming the etiology.
Probably, the number of viral copies was higher in
the vitreous. Interestingly, after introduction of the
antiviral treatment a sharp and significant decrease of
the number of viral copies was observed. At 6 months
post treatment, at a time when the lesions were
healed, a significant decrease of the number of viral
copies was observed in the AH. A positive residual
viral load at 1379 copies was still present in the
vitreous. At 10 months PCR was negative in the AH.
Our case demonstrates the utility of PCR for diag-
nosis and suggests that viral DNA persists in ocular
fluids for months in the presence of a healed
infection.
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